 |
|
Hepatic Dysfunction During Isoniazid Chemoprophylaxis in Renal Allograft Recipients
Paul A. Thomas, Jr, MD;
Martin F. Mozes, MD;
Olga Jonasson, MD
Arch Surg. 1979;114(5):597-599.
Abstract
• Hepatitis is a frequent complication of dialysis and renal transplantation; therefore, the occurrence of drug hepatotoxicity is an additional important consideration in renal allograft recipients. Azathioprine, needed for immunosuppression, and isoniazid, used for antituberculous chemoprophylaxis, are both potentially hepatotoxic. A retrospective study of 119 patients who received 126 renal allografts was done to estimate the probable incidence of isoniazid-related hepatic dysfunction. All patients in this series were administered isoniazid chemoprophylaxis. Posttransplantation hepatitis developed in 13 patients. Circumstantial evidence supported a presumptive diagnosis of isoniazid hepatotoxicity in three recipients. We concluded that routine isoniazid chemoprophylaxis is not justified in renal allograft recipients based on the probability of hepatotoxicity as contrasted to the infrequent occurrence of tuberculosis.
(Arch Surg 114:597-599, 1979)
Author Affiliations
From the Department of Surgery, University of Illinois Hospital, Chicago.
Footnotes
Accepted for publication Jan 9, 1979.
Reprint requests to Department of Surgery, University of Illinois Hospital, PO Box 6998, Chicago, IL 60680 (Dr Thomas).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Monitored Isoniazid Prophylaxis for Low-Risk Tuberculin Reactors Older Than 35 Years of Age: A Risk-Benefit and Cost-Effectiveness Analysis
Salpeter et al.
ANN INTERN MED 1997;127:1051-1061.
ABSTRACT
| FULL TEXT
Mycobacterial Infections in Renal Transplant Recipients: Seven Cases and a Review of the Literature
Lloveras et al.
Arch Intern Med 1982;142:888-892.
ABSTRACT
|
